BioMarin price target lowered to $62 from $66 at RBC Capital
RBC Capital analyst Luca Issi lowered the firm's price target on BioMarin to $62 from $66 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June relative